top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.

Biblioteca

MARC Lista (tabellare)
Synbiotics for the Management of Cancer / / edited by Neeraj Mishra, Shvetank Bhatt, Keshav Raj Paudel, Philip M Hansbro, Kamal Dua
Synbiotics for the Management of Cancer / / edited by Neeraj Mishra, Shvetank Bhatt, Keshav Raj Paudel, Philip M Hansbro, Kamal Dua
Edizione [1st ed. 2023.]
Pubbl/distr/stampa Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2023
Descrizione fisica 1 online resource (349 pages)
Disciplina 616.9940654
Soggetto topico Pharmacology
Cancer
Cancer - Treatment
Cancers
Cancer Therapy
ISBN 9789811975509
9789811975493
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Chapter 1_Introduction to Cancer -- Chapter 2_Effect of anticancer treatment approches on gut microbiota -- Chapter 3_Synbiotic: A promising approach for the treatment of cancer -- Chapter 4_Correlation between ROS and Synbiotics for effective treatment of cancer -- Chapter 5_Influence of synbiotics on inflammation and immune microenvironment for the treatment of cancer -- Chapter 6_Synbiotics in colorectal cancer -- Chapter 7_Synbiotics in cervical cancer -- Chapter 8_Synbiotics in prostate cancer -- Chapter 9_Synbiotics in gastric cancer -- Chapter 10_Synbiotics in lung cancer -- Chapter 11_Synbiotics in small cell pancretatic cancer -- Chapter 12_Synbiotics in breast cancer -- Chapter 13_Synbiotics in hepatocellular carcinoma -- Chapter 14_Synbiotics in ovarian cancer -- Chapter 15_Regulatory issues of synbiotics in cancer.
Record Nr. UNINA-9910683353703321
Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2023
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Systems Biomedicine Approaches in Cancer Research / / edited by Shailza Singh
Systems Biomedicine Approaches in Cancer Research / / edited by Shailza Singh
Edizione [1st ed. 2022.]
Pubbl/distr/stampa Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2022
Descrizione fisica 1 online resource (170 pages)
Disciplina 570.15195
Soggetto topico Synthetic Biology
Cancer
Bioinformatics
Cancer - Treatment
Cancer Biology
Computational and Systems Biology
Cancer Therapy
Càncer
Biometria
Proliferació cel·lular
Terapèutica
Soggetto genere / forma Llibres electrònics
ISBN 9789811919534
9789811919527
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Chapter 1_Systems Complexity in Cancer -- Chapter 2_Engineered Biotherapeutics through Synthetic Biology in Cancer -- Chapter 3_Cancer Immunotherapy: A Potential Convergence between Systems and Synthetic Biology -- Chapter 4_Cell Based Therapeutic Devices in Cancer -- Chapter 5_Case Studies on Medicinal Plants in Cancer Drug Discovery using System Approaches -- Chapter 7_Metabolic engineering and synthetic biology devices in treating Cancer -- Chapter 8_Cancer Biomarkers in the era of Systems Biology -- Chapter 9_Supervised vs Non-Supervised Learning to Combat Cancer -- Chapter 10_Designing Cancer Biological Systems using Synthetic Engineering -- Chapter 11_Biosystems and Genetic Engineering Tools in Cancer Theranostics -- Chapter 12_Role of HPC in Cancer Informatics -- Chapter 13_Statistical ML for Cancer Therapeutics -- Chapter 14_Data Mining and Knowledge Discovery in Cancer -- Chapter 15_TCGA Data from TensorFlow Optimization.
Record Nr. UNINA-9910586583603321
Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2022
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Taking charge of cancer : what you need to know to get the best treatment / / David Palma, MD, PhD ; foreword by Anthony Zietman, MD
Taking charge of cancer : what you need to know to get the best treatment / / David Palma, MD, PhD ; foreword by Anthony Zietman, MD
Autore Palma David
Pubbl/distr/stampa Oakland, California : , : New Harbinger Publications, Inc., , 2017
Descrizione fisica 1 online resource (274 pages) : illustrations
Disciplina 616.994
Soggetto topico Cancer
Cancer - Treatment
ISBN 1-62625-863-5
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910795922303321
Palma David  
Oakland, California : , : New Harbinger Publications, Inc., , 2017
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Taking charge of cancer : what you need to know to get the best treatment / / David Palma, MD, PhD ; foreword by Anthony Zietman, MD
Taking charge of cancer : what you need to know to get the best treatment / / David Palma, MD, PhD ; foreword by Anthony Zietman, MD
Autore Palma David
Pubbl/distr/stampa Oakland, California : , : New Harbinger Publications, Inc., , 2017
Descrizione fisica 1 online resource (274 pages) : illustrations
Disciplina 616.994
Soggetto topico Cancer
Cancer - Treatment
ISBN 1-62625-863-5
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910813929703321
Palma David  
Oakland, California : , : New Harbinger Publications, Inc., , 2017
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Tamoxifen [[electronic resource] ] : questions and answers
Tamoxifen [[electronic resource] ] : questions and answers
Pubbl/distr/stampa [Bethesda, Md.] : , : National Cancer Institute, , [2008]
Descrizione fisica 7 pages : digital, PDF file
Collana Fact sheet
Soggetto topico Cancer - Treatment
Breast - Cancer
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Altri titoli varianti Tamoxifen
Record Nr. UNINA-9910698576003321
[Bethesda, Md.] : , : National Cancer Institute, , [2008]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Tamoxifeno [[electronic resource] ] : preguntas y respuestas
Tamoxifeno [[electronic resource] ] : preguntas y respuestas
Pubbl/distr/stampa [Bethesda, Md.] : , : National Cancer Institute, , [2002]
Descrizione fisica 6 pages : digital, PDF file
Collana Hojas informativas
Soggetto topico Cancer - Treatment
Breast - Cancer
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione spa
Altri titoli varianti Tamoxifeno
Record Nr. UNINA-9910697362203321
[Bethesda, Md.] : , : National Cancer Institute, , [2002]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Targeted Cancer Therapy in Biomedical Engineering / / edited by Rishabha Malviya, Sonali Sundram
Targeted Cancer Therapy in Biomedical Engineering / / edited by Rishabha Malviya, Sonali Sundram
Edizione [1st ed. 2023.]
Pubbl/distr/stampa Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2023
Descrizione fisica 1 online resource (xxii, 941 pages, 211 illustrations, 204 illustrations in color) : illustrations
Disciplina 616.99406
Collana Biological and Medical Physics, Biomedical Engineering
Soggetto topico Medical physics
Cancer - Treatment
Biomedical engineering
Computer-aided engineering
Nanobiotechnology
Cancer - Imaging
Neoplasms - drug therapy
Neoplasms - diagnostic imaging
Biomarkers, Tumor
Biomedical Engineering
Tissue Engineering
Medical Physics
Cancer Therapy
Biomedical Engineering and Bioengineering
Computer-Aided Engineering (CAD, CAE) and Design
Cancer Imaging
ISBN 981-19-9786-1
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Strategies for Cancer Targeting: Novel Drug Delivery Systems Opportunities and Future Challenges -- Implementation of Biomedical Engineering Tools in Targeted Cancer Therapy: Challenges and Opportunities -- Exploration of tissue-engineered systems for cancer research -- Advancement of Tissue Engineered in Cancer treatment -- Immunotherapy: Targeting Cancer Cells -- Bioinformatics Tools to Discover and Validate Cancer Biomarkers -- Application of Biomaterials in Cancer Research -- Engineered Tissue in Cancer Research: Techniques, Challenges and Current status -- CADD for Cancer Therapy: Current and Future Perspective -- Leveraging Advancement in Robotics in the Treatment of Cancer -- Innovative Biomedical Equipment for Diagnosis of Cancer -- Detection of Cancer Biomarker by Advanced Biosensor.
Record Nr. UNINA-9910686477303321
Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2023
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Targeting oncogenic drivers and signaling pathways in lymphoid malignancies : from concept to practice / / edited by Owen A. O'Connor, Stephen Ansell, and John Seymour
Targeting oncogenic drivers and signaling pathways in lymphoid malignancies : from concept to practice / / edited by Owen A. O'Connor, Stephen Ansell, and John Seymour
Pubbl/distr/stampa Hoboken, New Jersey : , : John Wiley & Sons, Inc., , [2023]
Descrizione fisica 1 online resource (514 pages)
Disciplina 616.99406
Collana Precision cancer therapies
Soggetto topico Cancer - Treatment
Precision Medicine
Lymphoma - therapy
Signal Transduction
ISBN 1-119-81995-4
1-119-81993-8
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Intro -- Precision Cancer Therapies -- Contents -- List of Contributors -- Volume Foreword -- Volume Preface -- Series Preface -- Section I Biological Basis of the Lymphoid Malignancies -- 1 Fundamental Principles of Lymphomagenesis -- Take Home Messages -- Introduction -- How to Study Lymphomagenesis -- Before Lymphoma: The Gray Frontier Between Physiology and Pathology -- Driver Without Disease -- From In Situ Neoplasms to Asymptomatic Lymphomas -- Chronic Antigenic Stimulation as an Early Step of Lymphomagenesis -- The Cell of Origin Concept: A Classification Based on Physiology -- What Are the Hallmarks of Lymphoma? -- Epigenetics and Metabolism -- Apoptosis Escape -- Proliferation -- TCR/BCR Signaling -- Immune Escape -- Trafficking -- Microenvironment -- Conclusion -- Must Read References -- References -- 2 Identifying Molecular Drivers of Lymphomagenesis -- Take Home Messages -- Introduction -- Sequencing and Bioinformatics Methods -- Functional Validation of Drivers -- Common Themes in B- and T-cell Lymphoma -- Genetic Landscapes of Lymphomas -- Mature B-cell Lymphomas -- T-cell Lymphomas -- Genomic Subgrouping Approaches in DLBCL -- Challenges of Incorporating Genomic Subgrouping Approaches in Clinical Trials -- Leveraging Underlying Pathophysiology to Inform Therapeutic Consideration -- Conclusion -- Must Read References -- References -- 3 Characterizing the Spectrum of Epigenetic Dysregulation Across Lymphoid Malignancies -- Take Home Messages -- Introduction: Epigenetics and Lymphoid Malignancies -- Dysregulation of DNA Methylation and Modification of Histone Proteins -- Genes Involved in Histone Modification Implicated in Lymphomagenesis -- Enhancer of Zeste Homolog 2 (EZH2) -- CREB-binding Protein (CREBBP) and Histone Acetyltransferase P300 (EP300) -- The H3K4 Methyltransferase Family.
The Bromodomain and Extra-Terminal Domain (BET) Family -- Genes Involved in DNA Methylation Implicated in Lymphomagenesis -- DNA Methyltransferase 3A (DNMT3A) -- Ten-Eleven Translocation 1/2 (TET1/2) -- Isocitrate Dehydrogenase 2 (IDH2) -- The Epigenetic Landscape of Specific Lymphoid Malignancies -- Follicular Lymphoma -- Diffuse Large B-cell Lymphoma -- Marginal Zone Lymphoma -- Burkitt's Lymphoma -- Acute Lymphoblastic Leukemia -- Chronic Lymphocytic Leukemia -- Mantle Cell Lymphoma -- Hodgkin's Lymphoma -- Multiple Myeloma -- Peripheral T-cell Lymphoma - Not Otherwise Specified -- Angioimmunoblastic T-cell Lymphoma and PTCL with TFH Phenotype -- Anaplastic Large Cell Lymphoma -- Adult T-cell Leukemia/Lymphoma -- Intestinal T-cell Lymphoma -- Hepatosplenic T-cell Lymphomas -- NK/T Cell Lymphoma -- Mycosis Fungoides and Sezary's Syndrome -- Summary -- Must Read References -- References -- 4 Animal Models of Lymphoid Malignancies -- Take Home Messages -- Introduction -- Optimal Animal Models to Study Lymphoid Neoplasms -- Zebrafish Model -- Zebrafish Model of T-cell Neoplasms -- Zebrafish Model of B-cell Neoplasms -- Zebrafish Model of NK-cell Neoplasms -- Patient-Derived Xenograft Models in Zebrafish -- Fruit Fly Model -- Non-human Primate Model -- Mouse Models of Lymphoid Neoplasia -- Use of Animal Models in Translational Research -- Conclusions -- Must Read References -- References -- Section II Targeting the PI3 Kinase-AKT-mTOR Pathway -- 5 Principles of PI3K Biology and Its Role in Lymphoma -- Take Home Messages -- Introduction: Overview -- Four Decades of PI3K Signaling Research -- Class I PI3K Enzymes -- Isoforms -- Structural Organization -- Isoform-specific Functions -- The Essential Phospholipid Second Messenger PIP3 -- PI3K Pathway Effectors -- AKT, FOXO, and mTORC1 -- TEC Tyrosine Kinases -- Network Topology and Signal Robustness.
Dynamic PI3K Signaling in Lymphocyte Biology -- B-cell Development and Survival -- The Germinal Center (GC) Reaction -- TFH Cell Function -- Naïve and Effector T-cells -- Lessons from Monogenic Disorders -- Genetic PI3Kd Inactivation -- Genetic PI3Kd Hyperactivation -- Corrupted PI3K Signaling in Cancer -- The Success of PI3Kd Inhibition in Lymphoid Malignancies -- Quantitative Biology and Therapeutic Considerations -- Concluding Remarks -- Acknowledgments -- Must Read Reference -- References -- 6 Pharmacologic Differentiation of Drugs Targeting the PI3K-AKT-mTOR Signaling Pathway -- Take Home Messages -- Introduction -- PI3K Inhibitors Approved by the US Food and Drug Administration (FDA) -- PI3K Inhibitors in Clinical Development -- AKT Inhibitors -- mTOR Inhibitors -- Conclusions -- Must Read References -- References -- 7 Clinical Experience with Phosphatidylinositol 3-Kinase Inhibitors in Hematologic Malignancies -- Take Home Messages -- Introduction -- Idelalisib -- Copanlisib -- Duvelisib -- Umbralisib -- Parsaclisib -- Zandelisib -- Amdizalisib (HMPL-689) -- Conclusion -- Must Read References -- References -- 8 Clinical Experiences with Drugs Targeting mTOR -- Take Home Messages -- Introduction -- Rapamycin (Sirolimus) Rapamune® (Pfizer) and Generic Sirolimus -- The Rapamycin Analogs (Rapalogs) -- Temsirolimus (CCI-779 -- Torisel) -- Everolimus (RAD-001 -- Afinitor, Zortrees, Evertor) -- Summary of Lymphoma Studies of Everolimus -- Ridaforolimus -- Dual Inhibitors of mTORC1 and mTORC2 -- Side Effects of mTORC1 Inhibitors -- Future Directions for mTOR Inhibitors in Lymphoma -- Must Read References -- References -- 9 PI3 Kinase, AKT, and mTOR Inhibitors -- Take Home Messages -- Introduction -- PI3K Structure and Functions -- AKT Structure and Functions -- mTOR Structure and Functions -- PTEN as a Regulator of the PI3K/AKT/mTOR Pathway.
mTOR Inhibitors -- Temsirolimus: Phase 3 Trials -- PI3K and Dual PI3K/mTOR Inhibitors -- PI3K Isoforms and Expression Throughout the Body -- Immune Toxicity and Management -- Colitis -- Hepatitis -- Pneumonitis -- Skin Rash -- Homeostatic Toxicity -- Hypertension and Hyperglycemia -- Myelosuppression and Opportunistic Infection -- Myelosuppression -- Atypical Infection -- Vaccination -- Neuropsychiatric Problems -- PI3K Treatment in NHL -- AKT Inhibitors -- Conclusion -- Must Read References -- References -- Section III Targeting Programmed Cell Death -- 10 Principles for Understanding Mechanisms of Cell Death and Their Role in Cancer Biology -- Take Home Messages -- Introduction -- A Historical Perspective -- Apoptotic Pathways -- Other Cell Death Pathways -- The Role of Intrinsic Apoptosis in Normal Cells - Lessons from Gene Knockout Mice -- BCL2 Family Pro-survival Proteins -- BCL2 -- BCL-XL -- MCL-1 -- A1/BFL-1 -- BCL-W -- Combined Knockout of Pro-survival Proteins -- BCL2 Family Pro-apoptotic Effector Proteins -- BH3-only Proteins -- The Dysregulation of Apoptosis in Cancer -- Must Read References -- References -- 11 Pharmacologic Features of Drugs Targeting BCL2 Family Members -- Take Home Messages -- Introduction -- Historical Perspective: From the Discovery of BCL2 to Therapeutic Applications -- BCL2 as a Biomarker -- Targeting BCL2 Family Members -- Antisense Approaches for Targeting BCL2 -- Natural Anti-apoptotic Compounds -- Small Molecule Inhibitors of BCL2 Family Members -- Novel BCL2 Inhibitors on the Horizon -- Mechanisms of Resistance to BCL2 Inhibitors -- Novel Mechanisms to Overcome BCL2 Resistance -- Targeting MCL1 -- PROTAC Strategies for Targeting Apoptotic Family Members -- Conclusions -- Must Read References -- References -- 12 Clinical Experience with Pro-Apoptotic Agents -- Take Home Messages -- Introduction.
Safety and Toxicities of Pro-apoptotic Agents -- Tumor Lysis Syndrome -- Myeloid Compartment Toxicities and Infections -- Gastrointestinal Toxicities -- Thrombocytopenia and Navitoclax -- Efficacy of Venetoclax in Chronic Lymphocytic Leukemia/Small Cell Lymphoma -- Phase 1/2 Studies -- Combining Venetoclax with Conventional Chemotherapy in CLL/SLL -- Phase 3 Studies -- Venetoclax Re-treatment -- Efficacy of Venetoclax in Other B-cell Neoplasms -- Mantle Cell Lymphoma -- Follicular Lymphoma -- Diffuse Large B-cell Lymphoma and Other Aggressive B-cell Lymphomas -- Richter Transformation -- Waldenstrom's Macroglobulinemia -- Marginal Zone Lymphoma -- Acute Lymphoblastic Leukemia/Lymphoma -- Lessons from Venetoclax in Lymphoid Neoplasms Other than CLL/SLL -- Associations and Mechanisms of Resistance to Pro-apoptotic Agents -- Must Read References -- References -- 13 Promising Combinations of Drugs Targeting Apoptosis -- Take Home Messages -- Introduction: Background and Disease Perspective -- Clinical Development of BCL2 Inhibitors -- Venetoclax Monotherapy for CLL -- Venetoclax Plus CD20 Monoclonal Antibody for CLL -- Venetoclax Plus BTK Inhibitor for CLL -- Venetoclax Plus BTK Inhibitor and CD20 Monoclonal Antibody for CLL -- Venetoclax Plus Chemoimmunotherapy -- Venetoclax Toxicities and Side Effects in CLL -- TLS Risk Mitigation and Management in CLL -- Venetoclax-associated Neutropenia -- Risk for Progression and Resistance Mechanisms -- Current Knowledge Gaps and Opportunities for Future Work with Venetoclax -- Must Read References -- References -- Section IV Targeting the Cancer Epigenome -- 14 The Role of Epigenetic Dysregulation in Lymphoma Biology -- Take Home Messages -- Introduction: Germinal Center B (GCB)-cells and GCB-derived Lymphomas -- Mutations Altering DNA Modifications and Structure -- TET2.
Mutations Altering Writers of Histone Post-translational Modifications.
Record Nr. UNINA-9910830571103321
Hoboken, New Jersey : , : John Wiley & Sons, Inc., , [2023]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Targets of cancer diagnosis and treatment : ion transport in tumor biology / / Christian Stock and Luis A. Pardo, editors
Targets of cancer diagnosis and treatment : ion transport in tumor biology / / Christian Stock and Luis A. Pardo, editors
Pubbl/distr/stampa Cham, Switzerland : , : Springer, , [2022]
Descrizione fisica 1 online resource (280 pages)
Disciplina 616.994075
Collana Reviews of physiology, biochemistry and pharmacology
Soggetto topico Cancer - Diagnosis
Cancer - Treatment
Ion channels
ISBN 3-031-03994-7
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910568258003321
Cham, Switzerland : , : Springer, , [2022]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Tea & chemo : fighting cancer, living life / / Jackie Buxton
Tea & chemo : fighting cancer, living life / / Jackie Buxton
Autore Buxton Jackie
Pubbl/distr/stampa Chatham-Kent, [Ontario] : , : Urbane Publications Limited, , 2015
Descrizione fisica 1 online resource (114 p.)
Disciplina 616.99406
Soggetto topico Cancer - Treatment
Cancer - Patients - Attitudes
ISBN 1-910692-40-9
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910157413603321
Buxton Jackie  
Chatham-Kent, [Ontario] : , : Urbane Publications Limited, , 2015
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui